News | Molecular Imaging | February 01, 2017

Lightpoint Medical Announces Clinical Trial Results of Intraoperative Breast Cancer Surgery Imaging Technology

Data show molecular imaging agrees strongly with pathology and was straightforward to interpret

Lightpoint Medical, LightPath Imaging System, clinical study results, breast-conserving surgery, intraoperative molecular imaging, Journal of Nuclear Medicine

February 1, 2017 — Lightpoint Medical announced in December positive clinical trial results for its intraoperative imaging technology in breast cancer surgery. The first-in-human clinical trial showed that intraoperative molecular imaging was a feasible, low-risk, and accurate procedure for assessing tumor margins intraoperatively. The study was conducted by Guy's and St Thomas' Hospital London and published in the Journal of Nuclear Medicine.

Breast-conserving surgery (BCS), also called lumpectomy, is the primary treatment for early-stage breast cancer, yet approximately 1 in 4 patients undergoing BCS will need to undergo repeat surgery. Repeat operations are required so frequently because surgeons lack a means to precisely detect the cancer in the initial surgery. Intraoperative molecular imaging potentially provides a means to assess the extent of cancer during surgery and reduce the need for repeat operations.

The study's principal investigator, Prof. Arnie Purushotham from King's College London and Guy's Hospital, commented: "We're delighted to present these exciting first-in-human results on the use of intraoperative molecular imaging in breast-conserving surgery. This clinical trial showed that molecular imaging agreed strongly with gold standard pathology and was straightforward to interpret. Although the technology is still in its early days, we believe intraoperative molecular imaging holds considerable promise for improving clinical outcomes in breast cancer patients."

The LightPath Imaging System is CE Marked and approved for sale in the European Union. The clinical trial was supported by funding from Innovate UK, Cancer Research UK King's Health Partners Experimental Cancer Medicine Centre, Guy's and St Thomas' Charity, and the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London.

For more information: www.lightpointmedical.com

 

References

Grootendoorst MR et al. “Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery using 18F-FDG Cerenkov Luminescence Imaging - A First-in-Human Feasibility Study.” The Journal of Nuclear Medicine. Published Dec. 8, 2016. doi:10.2967/jnumed.116.181032

Related Content

Hologic Opens Learning and Experience Centre in Zaventem, Belgium
News | Women's Health | March 21, 2019
Hologic Inc. opened its first Learning and Experience Centre in Zaventem, Belgium. The state-of-the-art facility...
Improving Molecular Imaging Using a Deep Learning Approach
News | Nuclear Imaging | March 21, 2019
Generating comprehensive molecular images of organs and tumors in living organisms can be performed at ultra-fast speed...
QTbreasthealth Opens Breast Imaging Center in San Jose
News | Ultrasound Women's Health | March 20, 2019
QTbreasthealth has opened a new center in San Jose, Calif. The new location is now open and booking appointments for...
Older Biologic Age Linked to Elevated Breast Cancer Risk
News | Women's Health | March 19, 2019
Biologic age, a DNA-based estimate of a person’s age, is associated with future development of breast cancer, according...
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Fujifilm Launches Three New Software Tools for Aspire Cristalle Digital Mammography System
Technology | Mammography | March 15, 2019
Fujifilm Medical Systems USA announced it has fulfilled all U.S. Food and Drug Administration (FDA) regulatory...
Hologic Receives CE Mark for Three-in-One Omni Hysteroscope
News | Endoscopes | March 14, 2019
Hologic Inc. announced it has received a CE mark in Europe for its Omni hysteroscope, a three-in-one modular scope with...
CT, Mammograms Offer Clues to Preventing Heart Problems After Cancer Treatment
News | Cardio-oncology | March 13, 2019
An imaging procedure commonly performed before starting cancer treatment can provide valuable clues about a patient's...
Sponsored Content | Videos | Artificial Intelligence | March 13, 2019
At RSNA 2018, iCad showed how its...
Hologic Earns CE Mark for LOCalizer Wireless Breast Lesion Localization System
News | Breast Imaging | March 07, 2019
Hologic Inc. announced the granting of a CE Mark to the LOCalizer wireless radio frequency identification (RFID) breast...